TBPH Theravance Biopharma Inc.

32.58
+0.71  (2%)
Previous Close 31.87
Open 31.99
Price To book 7.27
Market Cap 1753764198
Shares 53,829,472
Volume 100,479
Short Ratio 16.46
Av. Daily Volume 317,813

SEC filingsSee all SEC filings

  1. 8-K - Current report 171017007
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171016326
  3. 8-K - Current report 171015161
  4. 8-K - Current report 171015138
  5. 8-K - Current report 17998288

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 2017.
Closed Triple - IMPACT
COPD
Approved June 21, 2013.
VIBATIV (telavancin hydrochloride) for injection
Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP)
Approved April 30, 2015.
BREO ELLIPTA
Asthma
Phase 2a data due 1H 2018.
TD-9855
nOH
Phase 3 data due 2H 2018.
Closed Triple - CAPTAIN
Asthma
NDA filing submission announced November 21, 2016.
Closed Triple
COPD
Phase 3 trials met primary endpoint. 12 month safety trial data released July 19, 2017 with NDA filing due 4Q 2017.
Revefenacin
COPD
Phase 2b data released August 2, 2017. Primary endpoint not met.
Velusetrag (TD-5108)
Gastroparesis
Phase 2 data released June 2016
TD-6450
Hepatitis C virus (HCV)
Phase 3 data due 2018 or 2019.
Telavancin
Bacteremia
Phase 3 first patient enrolled late February 2015. Data due 2017
Telavancin
Staphylococcus aureus bacteremia
Phase 3 data due in 2016
TD-4208
Chronic obstructive pulmonary disease (COPD

Latest News

  1. Theravance Biopharma to Present at the Cantor Fitzgerald Global Healthcare Conference
  2. Mylan Plans to File Application for Revefenacin in Late 2017
  3. Theravance Biopharma Highlights Approval of Trelegy Ellipta (Closed Triple) as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US
  4. Theravance Biopharma Highlights GlaxoSmithKline and Innoviva's Receipt of Positive Opinion from CHMP in Europe for Trelegy Ellipta (Closed Triple)
  5. Why Amgen, Lilly, J&J Are Interested In These Small Biotechs
  6. Theravance Biopharma, Inc. breached its 50 day moving average in a Bullish Manner : TBPH-US : September 14, 2017
  7. ETFs with exposure to Theravance Biopharma, Inc. : September 14, 2017
  8. See what the IHS Markit Score report has to say about Theravance Biopharma Inc.
  9. Theravance Biopharma, Inc. :TBPH-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017
  10. Theravance Biopharma to Present at the Morgan Stanley 15th Annual Global Healthcare Conference
  11. Edited Transcript of TBPH earnings conference call or presentation 8-Aug-17 9:00pm GMT
  12. Theravance Biopharma, Inc. Reports Second Quarter 2017 Financial Results and Provides Business Update
  13. Theravance Biopharma Reports Encouraging Data from First Cohort of Patients in Phase 1b Clinical Trial of TD-1473 in Ulcerative Colitis
  14. Investor Network: Theravance Biopharma Inc to Host Earnings Call
  15. Corporate News Blog - Theravance Biopharma’s Velusetrag Successful in Mid-Stage Gastroparesis Study
  16. Theravance Biopharma Announces Positive Top-Line Results from Phase 2b Study of Velusetrag (TD-5108) in Patients with Gastroparesis

SEC Filings

  1. 8-K - Current report 171017007
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171016326
  3. 8-K - Current report 171015161
  4. 8-K - Current report 171015138
  5. 8-K - Current report 17998288
  6. UPLOAD [Cover] - SEC-generated letter
  7. CORRESP [Cover] - Correspondence
  8. 8-K - Current report 17854980
  9. 8-K - Current report 17828328
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 17828314